IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of ...

Haisco Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Researchers at Inventisbio ...

Nimbus' pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in development for microsatellite instability high (MSI-H) tumors, as well as a diverse portfolio of preclinical ...

In addition, Eikon’s early-stage pipeline features two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for ...

Haisco Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

"Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in ...

Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...

IDE275 (GSK959), a potential best-in-class Werner Helicase (WRN) inhibitor, has demonstrated selective preclinical efficacy in the high microsatellite instability (MSI-H) solid tumor setting ...